ARCT
Arcturus Therapeutics Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.82
+1.67%Aug 7, 2026, 12:04 UTC
Arcturus Therapeutics Holdings Inc. held its Q2 2026 earnings call on August 7, 2026.
Source:Aug 6, 2026, 22:21 UTC
Arcturus Therapeutics reported a second-quarter loss of $0.84 per share, beating the Zacks Consensus Estimate of a loss of $1.07, and compared to a loss of $0.34 per share a year ago.
Source:Aug 6, 2026, 22:04 UTC
Arcturus Therapeutics regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform after ending its collaboration with CSL Seqirus.
Source:Jul 2, 2026, 11:00 UTC
Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
Source:Jul 2, 2026, 00:00 UTC
Arcturus Therapeutics signed a Master Services Agreement with Thermo Fisher Scientific for development services for ARCT-032, an mRNA therapeutic for cystic fibrosis, with Thermo Fisher contributing up to $40 million in clinical manufacturing services and Arcturus engaging PPD for up to $40 million in CRO services.